Insulin Degludec: Nursing Drug Guide, Hypoglycemia & Dosing
Insulin degludec (Tresiba) is an ultra-long-acting basal insulin with a flat profile beyond 24 hours. The highest-stakes nursing failures are hypoglycemia from duplicate basal coverage, wrong insulin or strength, pen-to-syringe transfer of FlexTouch contents, and giving a basal dose during an untreated low.
Hypoglycemia is the most common adverse reaction with insulin degludec and may be life-threatening. Tresiba is contraindicated during hypoglycemia. Never share FlexTouch pens or needles between patients. Verify insulin name, concentration (U-100 vs U-200), and dose before every injection—accidental mix-ups among insulin products are reported. Labeling warns that transferring Tresiba from the FlexTouch pen into a syringe can cause overdosage and severe hypoglycemia. Increased glucose monitoring is required with dose changes, meal or activity changes, interacting drugs, renal or hepatic impairment, and hypoglycemia unawareness. In type 1 diabetes, Tresiba must be used with mealtime insulin.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Verify product, U-100 vs U-200, and dose on every pass. Hold when hypoglycemic or when two basal insulins appear on the MAR. Never draw Tresiba from a pen into a syringe. After regimen changes, increase glucose checks because the long action of degludec may delay recovery from hypoglycemia.
Most common brand names
TRESIBA (insulin degludec injection) is the primary U.S. brand in FDA labeling. Concentrations include U-100 (100 units/mL) as a 3 mL FlexTouch prefilled pen and 10 mL multiple-dose vial, and U-200 (200 units/mL) as a 3 mL FlexTouch prefilled pen only. The U-100 FlexTouch delivers doses in 1-unit increments (up to 80 units per injection); the U-200 FlexTouch delivers in 2-unit increments (up to 160 units). Always match product, concentration, and device on the MAR to the supply in hand.
Why we give it — Indications
TRESIBA (insulin degludec) is indicated to improve glycemic control in patients 1 year of age and older with type 1 or type 2 diabetes mellitus. It is not recommended for diabetic ketoacidosis—treat DKA with insulin per inpatient protocol, not basal degludec alone. In type 1 diabetes, Tresiba must be used with short-acting mealtime insulin such as insulin lispro.
| Use | Detail |
|---|---|
| Type 1 diabetes | Basal insulin with mandatory mealtime insulin (e.g., lispro); not for DKA alone |
| Type 2 diabetes | Basal insulin when oral agents such as metformin and lifestyle measures are insufficient |
| Not for DKA | Not recommended for diabetic ketoacidosis—use inpatient insulin per protocol, not basal degludec alone |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Insulin degludec is a long-acting human insulin analog with a prolonged, relatively flat glucose-lowering profile. Like other insulins, it stimulates peripheral glucose uptake and inhibits hepatic glucose production. Nursing relevance: basal insulin lowers glucose continuously—hypoglycemia risk persists with missed meals, increased activity, overlapping basal orders, or dose errors, and the long duration may delay recovery from hypoglycemia compared with shorter-acting insulins per Tresiba labeling.
Dosing overview
Individualize Tresiba based on metabolic needs, blood glucose monitoring, and glycemic goals. Recommended interval between dose increases is 3 to 4 days. Do not perform dose conversion when using Tresiba U-100 or U-200 FlexTouch pens—the dose window shows units to deliver.
Administration timing
- Adults: inject once daily at any time of day
- Pediatrics: inject once daily at the same time every day
- Pediatric patients needing <5 units/day: use Tresiba U-100 vial per labeling
Missed dose (adults): inject during waking hours upon discovering the missed dose; ensure at least 8 hours between consecutive Tresiba injections. Pediatrics: contact healthcare provider for guidance and monitor glucose more frequently until the next scheduled dose.
Onset, peak, duration, and half-life
| Parameter | Value (Tresiba labeling) | Nursing relevance |
|---|---|---|
| Duration of action | Ultra-long basal profile; glucose lowering beyond 24 hours at steady state | Hypoglycemia may persist or recur—longer observation after overdose than with shorter-acting insulins |
| Onset | Gradual; not intended for meal coverage alone | Do not substitute for mealtime insulin; type 1 requires concomitant bolus insulin |
| U-100 FlexTouch | 1-unit increments; up to 80 units per injection | Match order to U-100 pen or 10 mL vial |
| U-200 FlexTouch | 2-unit increments; up to 160 units per injection | Never transfer to syringe; pen window shows units—no manual conversion |
| Site variation | Injection site, blood supply, and temperature affect action | Rotate sites; lipodystrophy or amyloidosis at site alters absorption—changing site may cause hypo or hyperglycemia |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Point-of-care blood glucose and trend since last insulin dose
- Blood glucose value and trend; oral intake and NPO status; activity level planned for next 24 hours
- Verify insulin name, concentration (U-100 vs U-200), dose, route, and device match the order; follow high-alert medication administration protocols
- Inspect solution—Tresiba should be clear and colorless; do not use if cloudy or particulate
- Review basal insulin, oral agents, and interacting drugs; complete medication reconciliation on admission and when new drugs start
Contraindications
- During episodes of hypoglycemia
- Hypersensitivity to insulin degludec or excipients (anaphylaxis reported)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Other antidiabetics / ACE inhibitors / fibrates | Increased hypoglycemia risk (labeling) | Increase glucose monitoring; expect dose adjustments with prescriber/pharmacy |
| Sympathomimetics (e.g., albuterol) | May increase glucose; may need higher insulin doses (labeling) | Monitor glucose when bronchodilator therapy intensifies |
| Corticosteroids, diuretics, atypical antipsychotics | May decrease glucose-lowering effect | Monitor for hyperglycemia when these drugs start or stop |
| Beta-blockers (e.g., metoprolol) | May blunt hypoglycemia warning signs (labeling) | Do not rely on tachycardia; assess hypoglycemia symptoms and glucose directly |
| Thiazolidinediones (TZDs) | Fluid retention and heart failure risk when combined with insulin | Monitor weight, edema, and heart failure symptoms; notify prescriber if worsening |
| Alcohol | Variable effect on glucose; hypoglycemia risk | Assess intake; teach to avoid drinking on an empty stomach |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Subcutaneous only (U-100 or U-200): Inject subcutaneously into the thigh, upper arm, or abdomen per labeling. Rotate injection sites within the same region. Adults: once daily at any time of day. Pediatrics: once daily at the same time every day. Never share FlexTouch pens, needles, or syringes between patients.
- Always read the insulin label before injection—accidental mix-ups between basal and rapid-acting insulins are reported
- Inspect solution—clear and colorless only; do not use if cloudy or particulate
- U-100: FlexTouch pen (1-unit increments, up to 80 units per injection) or 10 mL vial; for pediatric doses <5 units/day use U-100 vial per labeling
- U-200: FlexTouch pen only (2-unit increments, up to 160 units); do not transfer to a syringe, give IV, use in pumps, or mix with other insulins
- Do not dilute or mix Tresiba with any other insulin or solution
- Pair each dose with point-of-care glucose checks per protocol; increase monitoring when the regimen changes
Labeling warns that transferring Tresiba from the FlexTouch pen into a syringe can cause overdosage and severe hypoglycemia. If the patient is hypoglycemic, NPO without an alternate plan, or duplicate basal insulins appear on the MAR, hold Tresiba and notify the prescriber or pharmacist.
Expected therapeutic response
- Fasting and between-meal glucose trends improve over days to weeks when basal dose matches intake and activity
- Downward trend in HbA1c with consistent adherence and coordinated mealtime insulin in type 1
- No recurrent symptomatic hypoglycemia—especially overnight or when meals are skipped
- Stable weight and absence of unexplained nocturnal lows after regimen changes
Red flags — Stop and act
Hold insulin degludec (Tresiba) and escalate per protocol when:
- Documented or symptomatic hypoglycemia—treat before any additional basal dose
- Confusion, seizure, or loss of consciousness (severe hypoglycemia)
- Patient is NPO without alternate plan, has inadequate oral intake during acute illness, or persistent vomiting
- Cloudy or particulate insulin; wrong product or concentration (U-100 vs U-200); suspected pen-to-syringe transfer; duplicate basal insulin on MAR
- Suspected insulin overdose or pen-to-syringe transfer—monitor glucose frequently and treat hypoglycemia per protocol
- Signs of systemic hypersensitivity (whole-body rash, wheezing, hypotension)
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Hypoglycemia | Most common; may be severe or life-threatening (labeling) | Treat per protocol; hold dose; increase monitoring with regimen changes |
| Hypokalemia | All insulins shift potassium intracellularly; risk with IV use (labeling) | Monitor potassium in at-risk patients; review BMP when clinically indicated |
| Injection-site reactions / lipodystrophy | Local allergy, lipohypertrophy, lipoatrophy; amyloidosis at site reported postmarketing | Rotate sites; repeated injections into affected areas may cause hyperglycemia; site change may cause hypoglycemia |
| Weight gain / edema | Reported with insulin therapy, especially after intensification | Document weight trends; assess for heart failure if on TZD plus insulin |
| Hypersensitivity | Local or systemic including anaphylaxis (labeling) | Discontinue Tresiba; treat per emergency protocol |
| Medication errors | Wrong insulin product substituted; U-200 drawn into syringe (labeling) | Independent double-check; never transfer U-200 from pen to syringe |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Excess insulin administration causes hypoglycemia and hypokalemia per TRESIBA labeling. There is no specific antidote.
Management (FDA labeling)
- Mild hypoglycemia: oral glucose; adjust dose, meal pattern, or activity; continue monitoring
- Severe hypoglycemia with coma or seizure: IM or SC glucagon or concentrated IV glucose; sustained carbohydrate intake and observation because hypoglycemia may recur after apparent recovery
- Correct hypokalemia appropriately if present
- Contact local poison control or toxicology services per facility protocol for significant overdose
Look-alike / sound-alike and error prevention
- Tresiba (degludec) vs Toujeo/Lantus (glargine) vs Levemir (detemir)—all are basal insulins; verify generic name and concentration on every pass
- Tresiba vs rapid-acting insulins (lispro, aspart)—accidental substitution causes severe hypo or hyperglycemia; read label each time
- U-100 vs U-200 Tresiba—U-200 delivers twice the units per volume; never draw U-200 into a U-100 syringe or transfer from pen to syringe
- Duplicate basal coverage—degludec plus insulin glargine on the MAR without a switch order
- Pen dose window—do not manually convert units between U-100 and U-200 pens; use the device matched to the order
- “HS basal” given twice—independent double-check when handoffs or regimen changes occur
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Independent double-check | Two nurses verify high-alert insulin product, concentration, and units before basal administration |
| Once-daily timing | Adults may rotate injection time; pediatrics need same clock time daily—document actual time given |
| NPO / illness | Hold or reduce per prescriber when intake drops; do not continue home basal dose unchanged during acute illness without review |
| Regimen change | Switching from glargine or NPH requires increased glucose monitoring per labeling |
| Pen storage | Keep pen at room temperature after first use per labeling; never share device |
| Commonly missed | Continuing home basal plus new hospital basal; drawing pen contents into a syringe “for accuracy” |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Higher hypoglycemia risk; symptoms may be subtle—monitor glucose proactively |
| Renal impairment | Increased hypoglycemia risk; more frequent dose adjustment and glucose monitoring (labeling) |
| Hepatic impairment | Increased hypoglycemia risk; reduced gluconeogenesis (labeling) |
| Hypoglycemia unawareness / autonomic neuropathy | Blunted adrenergic symptoms; increase monitoring frequency |
| Beta-blocker therapy | May mask tachycardia and tremor—do not rely on adrenergic cues alone |
| Pregnancy | Available human data with Tresiba have not identified a clear drug-associated risk of major birth defects or miscarriage; poorly controlled diabetes in pregnancy increases maternal and fetal risk—individualize insulin and glucose targets per obstetric plan (labeling) |
| Lactation | No data on insulin degludec in human milk (labeling); LactMed notes exogenous insulin in breast milk is generally compatible with breastfeeding—monitor infant and maternal glucose |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Pre-meal and bedtime capillary blood glucose (frequency per protocol); increase monitoring with dose or regimen changes
- Signs of hypoglycemia and hyperglycemia—especially after site rotation away from lipodystrophy
- Potassium in patients at risk of hypokalemia (especially if hypoglycemia is treated with IV glucose per protocol)
- Weight, edema, and heart failure symptoms if TZD co-therapy
- Injection sites for lipodystrophy, redness, or swelling
Document
- Insulin product, concentration, units, route, site, and time given (especially when adult timing varies)
- Hypoglycemia events, treatment, and prescriber/pharmacy notification
- Hold reasons (NPO, low glucose, wrong product) and restart orders
Patient teaching
- Take Tresiba once daily as prescribed—adults may inject at any time of day; children should use the same time each day
- If you miss a dose, follow prescriber instructions (adults: inject when awake if at least 8 hours since last dose; children: contact your care team)
- Always check the insulin label and concentration before each dose; U-200 must stay in its pen—never draw it into a syringe
- Recognize hypoglycemia and carry fast-acting sugar; teach family when to give glucagon if prescribed
- Rotate injection sites; report lumps, pits, or recurring redness at sites
- Never share your pen or needles; tell clinicians about all insulins you use at home
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Blood glucose below facility hypoglycemia threshold or symptomatic hypoglycemia
- Patient is NPO or has inadequate oral intake without an alternate plan during acute illness
- Known hypersensitivity to insulin degludec or cloudy/particulate solution
- Insulin product, concentration (U-100 vs U-200), or device does not match the order
- Suspected U-200 transfer to a syringe or wrong-insulin administration—assess glucose and notify immediately
- Duplicate basal insulin orders (e.g., degludec and glargine) without a documented switch plan
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Basal insulin is a high-alert medication on medical-surgical units. Embed product verification, concentration checks, and duplicate-basal screening into every administration pass—not only on diabetes specialty rounds.
1. Check-before-you-give protocol
- Right patient, drug (insulin degludec), concentration (U-100 vs U-200), dose, route, and time
- Glucose value and trend since last insulin dose
- NPO status, oral intake, and activity plan for the next 24 hours
- Independent double-check for insulin name and units when policy requires
2. High-alert and safety badge
High-alert insulin — hypoglycemia and product-concentration errorsTreat pen-to-syringe transfer attempts and duplicate basal orders with the same urgency as wrong-insulin events.
3. Clinical workflow: hold and question rules
- NPO or acute illness with poor intake: hold or reduce basal insulin per prescriber/pharmacy and increase glucose checks
- Glucose below target: treat hypoglycemia and hold Tresiba until safe and reviewed
- Regimen change (new basal or steroid): reconcile MAR and increase monitoring per labeling
4. Critical teach-back questions
- “How will you know this is Tresiba and not your mealtime insulin?” (Patient should name label check, pen color/device, or pharmacy teach-back.)
- “What should you do if you miss a dose or have a low blood sugar?” (Patient should describe glucose check, fast sugar or glucagon if prescribed, and contacting the care team before the next dose.)
5. Care coordination
Pharmacist: Product/concentration verification, duplicate basal review, interaction review, U-200 counseling
Prescriber / diabetes educator: Basal titration, sick-day rules, switching from other basal insulins, mealtime insulin coordination in type 1
🧠 Quick mental checklist
- Right insulin name, U-100 vs U-200, and units?
- Is glucose already low or trending down?
- Only one basal insulin on the MAR?
- Any NPO, missed meals, or new steroids or beta-blockers?
- After hypoglycemia treatment, is Tresiba held and glucose repeating?
Insulin Degludec NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for insulin degludec hypoglycemia and meal-linked bolus timing using a tabbed inpatient case (MAR, labs, Vitals, nursing notes), then priority action, cue recognition (SATA), glucose trend interpretation, documentation cloze, ordered response, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
68-year-old with type 2 diabetes admitted for heart failure exacerbation. Home TRESIBA 6 units before each meal and insulin glargine 14 units at bedtime. NPO after midnight for cardiology consult in the morning. The nurse is reviewing the 0730 medication pass and breakfast tray status.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
- TRESIBA (insulin degludec) 22 units subcutaneous once daily — scheduled 2100; not yet given
- Insulin glargine 20 units subcutaneous HS — also on MAR (duplicate basal—pharmacy reviewing)
- Insulin lispro 4 units with meals — lunch held (NPO for procedure)
- Metoprolol 25 mg PO twice daily
- Diet: NPO after midnight for cardiac catheterization
- 2045 point-of-care glucose: 54 mg/dL (1800: 168 mg/dL; 1200: 142 mg/dL)
- Admission HbA1c: 8.6%
- Creatinine 1.4 mg/dL (baseline 1.0); eGFR 52 mL/min/1.73 m²
- Potassium 3.9 mEq/L
- BP 108/62 mmHg; HR 92/min (on home metoprolol)
- Temp 36.8 °C; SpO2 96% on room air
- Weight 84 kg (admission); no IV insulin infusion
- Patient reports dizziness when standing—check glucose before assuming orthostasis alone
- 2100: Patient diaphoretic, slow to answer; capillary glucose 54 mg/dL
- MAR shows both insulin glargine 20 units HS and Tresiba 22 units HS—pharmacy paged
- Previous shift note: student drew “extra units” from U-200 pen into syringe—supervisor notified
- Hypoglycemia treatment started; Tresiba held pending prescriber review
Answer key & rationale
Frequently asked questions
When should insulin degludec (Tresiba) be held?
Do not administer during hypoglycemia or known hypersensitivity. Hold and clarify when glucose is below facility threshold, the patient is NPO without an alternate plan, intake is inadequate during acute illness, the product or concentration does not match the order, or duplicate basal insulins appear on the MAR. Never transfer pen contents to a syringe.
What is the difference between Tresiba U-100 and U-200?
Both contain insulin degludec. U-100 is available as a FlexTouch pen, 10 mL vial, and for pediatric doses under 5 units/day. U-200 is 200 units/mL in a FlexTouch pen only. The pen dose window shows units without conversion. Never draw Tresiba from a pen into a syringe.
What is the antidote for insulin degludec overdose?
No specific antidote. Treat hypoglycemia with oral glucose or, if severe, glucagon or concentrated IV glucose with continued observation because hypoglycemia may recur. The long action of degludec may delay recovery. Contact local poison control or toxicology services per facility protocol.
How do you switch to Tresiba from another basal insulin?
Make changes under close supervision with increased glucose monitoring. Adults may start at the same daily long-acting unit dose; pediatric patients may start at 80% to reduce hypoglycemia risk. Type 1 diabetes still requires mealtime insulin.
Can Tresiba be mixed with other insulins?
No. Do not dilute or mix with other insulins or solutions. Do not give IV or via pump. Administer mealtime insulin as separate injections.
What adverse effects should nurses monitor?
Hypoglycemia is most common and may be life-threatening. Also monitor for hypokalemia, hypersensitivity, injection-site reactions, lipodystrophy, edema, weight gain, and heart failure symptoms with TZDs. Beta-blockers may blunt hypoglycemia warning signs.
References
- U.S. National Library of Medicine. TRESIBA (insulin degludec) injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afb63b26-5f28-4679-8a8b-5933ddf77fdc
- Drugs and Lactation Database (LactMed). Insulin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK500991/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.